Synergistic Stimulation of Adrenergic Receptors for the Treatment of Obesity

Important results from the project

The SYNSTAR program has successfully achieved its objectives, meeting all predetermined milestones, except for WP5. Here, the ongoing clinical trial has struggled with the timeline, but has been granted a one-year extension. In the context of partnering discussions, we have achieved all milestones except for the last one, which involves the completion of out-licensing documentation.

Expected long term effects

The SYNSTAR team has made significant progress in all our endeavours. We have synthesized hundreds of new ß-AR agonists, rigorously screened four for ADME, and conducted tests on two in obese rodents. Furthermore, we have performed detailed pathway analysis, which has guided the selection of a pre-candidate drug. Currently, a clinical study is in progress, and efforts such as patent filings and partner discussions are actively underway. The team is proud to report that they have successfully reached the majority of its milestones.

Approach and implementation

The proposed plan has been well executed, resulting in significant progress. We successfully synthesized numerous ß-AR agonists, rigorously screened candidates including testing four candidates for ADME, and conducted tests on two obese rodent models. Our detailed pathway analysis, ongoing clinical studies, patent applications, and active partner discussions demonstrate the comprehensive nature of our work. Most importantly, we have achieved most of our milestones, solidifying the success of our program.